Lv1
38 积分 2025-11-03 加入
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
6个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
6个月前
已完结
Claudin 18.2 as a novel therapeutic target
6个月前
已完结
Zolbetuximab moves into the SPOTLIGHT
6个月前
已完结
皖公网安备34019202002308
